Combinatons of Sacituzumab govitecan plus enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma: the Double Antibody Drug conjugate (DAD) and Double Antibody Drug Conjugate with Immunotherapy (DAD-IO) Phase I/II trial
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Dana-Farber/Mass General Brigham Cancer Care
This research is being done to study the safety and efficacy of two drug combinations. The first combination is Sacituzumab govitecan and enfortumab vedotin, and the second is Sacituzumab govitecan in combination with enfortumab vedotin and pembrolizumab